Access

News and Views

Nature 412, 281-282 (19 July 2001) | doi:10.1038/35085665

Open Innovation Challenges

New-age drug meets resistance

Frank McCormick

Top

A new sort of anticancer drug, designed to suppress the wayward protein that causes a type of leukaemia, is under the spotlight. Biological detective work has now revealed how this cancer becomes resistant to the drug.

Gleevec is the anticancer drug that everybody has been talking about. Known during its development as STI-571, this drug was rushed to market so quickly that Novartis, the company that developed it, had no time to clear a new trade name.